Zacks Investment Research upgraded shares of Kezar Life Sciences (NASDAQ:KZR) from a hold rating to a buy rating in a report published on Saturday morning. They currently have $20.00 target price on the stock.
According to Zacks, “Kezar Life Sciences, Inc. is a bio-technology company. It discovers and develops molecule therapeutics and medicines such as protein homeostasis for autoimmune disorders. The company’s product pipeline consists of KZR-616 which is in clinical stage. Kezar Life Sciences, Inc. is headquartered in South San Francisco, California. “
KZR has been the subject of several other reports. William Blair reaffirmed an outperform rating on shares of Kezar Life Sciences in a research note on Tuesday, March 12th. ValuEngine downgraded shares of Kezar Life Sciences from a buy rating to a hold rating in a research note on Thursday, December 13th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $24.33.
KZR opened at $18.19 on Friday. Kezar Life Sciences has a 1-year low of $14.77 and a 1-year high of $36.33.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC increased its position in shares of Kezar Life Sciences by 12.6% during the fourth quarter. FMR LLC now owns 2,849,233 shares of the company’s stock worth $67,242,000 after acquiring an additional 318,852 shares in the last quarter. EcoR1 Capital LLC increased its position in shares of Kezar Life Sciences by 1.3% during the third quarter. EcoR1 Capital LLC now owns 1,288,198 shares of the company’s stock worth $27,580,000 after acquiring an additional 16,000 shares in the last quarter. BB Biotech AG bought a new stake in shares of Kezar Life Sciences during the fourth quarter worth about $19,315,000. BlackRock Inc. increased its position in shares of Kezar Life Sciences by 1.9% during the fourth quarter. BlackRock Inc. now owns 245,932 shares of the company’s stock worth $5,804,000 after acquiring an additional 4,486 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Kezar Life Sciences by 126.7% during the fourth quarter. Geode Capital Management LLC now owns 58,046 shares of the company’s stock worth $1,369,000 after acquiring an additional 32,441 shares in the last quarter. 48.89% of the stock is owned by hedge funds and other institutional investors.
Kezar Life Sciences Company Profile
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Featured Article: How Short Selling Works
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.